CEACAM6: A potential prognostic biomarker and therapeutic target in cholangiocarcinoma

Jia-Qi Guo; Shi-Jia Dai; Yang Liu; Zhen-Gang Yuan

doi:10.1002/ctd2.70154

Clinical and Translational Discovery ›› 2026, Vol. 6 ›› Issue (3) :e70154 DOI: 10.1002/ctd2.70154

INVITED LETTER

CEACAM6: A potential prognostic biomarker and therapeutic target in cholangiocarcinoma

Author information +

History +

PDF (445KB)

Cite this article

Download citation ▾

Jia-Qi Guo, Shi-Jia Dai, Yang Liu, Zhen-Gang Yuan. CEACAM6: A potential prognostic biomarker and therapeutic target in cholangiocarcinoma. Clinical and Translational Discovery, 2026, 6 (3) : e70154 DOI:10.1002/ctd2.70154

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Banales JM, Rodrigues PM, Affò S, et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol. 2026;23:65-96.

[2]	Benson AB, D'Angelica MI, Abrams T, et al. NCCN guidelines® insights: biliary tract cancers, version 2.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2023;21:694-704.

[3]	Dai S-J, Tan J-Q, Guo J-Q, et al. CEACAM6 silencing suppresses tumour growth and sensitises cholangiocarcinoma to cisplatin. Clinical and Translational Discovery. 2025:1-17.

[4]	Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J Hepatol. 2022;76:1109-1121.

[5]	Duan M, Leng S, Mao P. Cisplatin in the era of PARP inhibitors and immunotherapy. Pharmacol Ther. 2024;258:108642.

[6]	Kang J, Brajanovski N, Chan KT, et al. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduction Targeted Ther. 2021;6:323.

[7]	Nakazawa Y, Miyano M, Tsukamoto S, et al. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models. Nat Commun. 2024;15:2192.

[8]	Li Y, Zhu X, You J, et al. Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. Heliyon. 2022;8:e10775.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.